AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06505226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual meditation
Description: virtually guided meditation via Zoom
Study NCT06375681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual and / or Auditory Cognitive Tasks (1)
Description: Seven sessions (\~45-75 minutes) of cognitive tasks in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements.
Study NCT06375681 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visual and / or Auditory Cognitive Tasks (2)
Description: Two sets of 10 sessions (\~20 minutes) of cognitive tasks either at home or in the lab.~Participants asked to view visual stimuli (such as black and white lines, letters, simple shapes like triangles, circles, and squares) presented on a computer or television screen and/or listen to auditory stimuli (such as pure tones) presented via headphone or speakers and asked to make simple judgements.
Study NCT06133023 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plastic stent
Description: EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the plastic stent group, two (at least one) 7-Fr double pigtail stents will be placed. Following EUS-guided puncture of a pseudocyst, a guidewire will be coiled within the lesion, and another guidewire will be inserted alongside the prepositioned guidewire. The puncture tract will be dilated if needed.
Study NCT06133023 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAMS
Description: EUS-guided drainage will be conducted under endosonographic and fluoroscopic guidance within 72 hours of the randomisation. A linear echoendoscope will be advanced to the stomach or duodenum with moderate sedation, and the targeted pseudocyst will be visualised and punctured under endosonographic guidance. In cases with an insufficient improvement in inflammatory indicators (i.e., body temperature, white blood cell count, and C-reactive protein), the investigators will perform additional interventions including the addition of or replacement with a plastic stent or LAMS and/or percutaneous drainage if needed.~In the LAMS group, a LAMS with electrocautery enhanced delivery will be placed (Hot AXIOS; Boston Scientific Japan, Tokyo, Japan). A guidewire or dilator will be used if needed.
Study NCT05547672 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroMems artificial urinary sphincter
Description: Implantation of the device
Study NCT05434234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL201
Description: Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.
Study NCT05486767 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transient elastography
Description: Both tests belong to the group of non-invasive tests for liver fibrosis (transient elastography belongs to the imaging-based tests and FIB-4 to the blood-based tests)
Study NCT06544720 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCG142 TCR-T cells
Description: Monotherapy of SCG142
Study NCT04637945 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ACRB
Description: Product will be consumed once daily, preferably with breakfast.
Study NCT04637945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Product will be consumed once daily, preferably with breakfast.
Study NCT05322031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Patiens who underwent a a period of stabilization with aripiprazole in oral formulation that begin therapy with long-acting aripiprazole, or already in therapy with long-acting aripiprazole from no more than two weeks.
Study NCT03971084 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar free gum without CPP-ACP
Description: Sugar free gum without CPP-ACP, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Study NCT03971084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar free gum with CPP-ACP
Description: Sugar free gum with 18.8 mg CPP-ACP per gum, consumed 5 times a day, for 20 min each time, within 5 minutes after 3 main meals plus 2 snacks occasion, during 14 days.
Study NCT05293652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Iontophoresis
Description: Hydrocortisone iontophoresis
Study NCT05293652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phonophoresis
Description: Hydrocortisone Phonophoresis
Study NCT05293652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional PT program
Description: Ultrasound and deep friction massage
Study NCT06118658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tislelizumab
Description: About 30 patients who underwent radical gastrectomy or enterectomy with gastric adenocarcinoma or esophagogastric junction adenocarcinoma with postoperative pathological stage III or intestinal adenocarcinoma with postoperative pathological stage T1-3N2M0 or T4N+M0(American Joint Committee on Cancer,AJCC 8th Edition Cancer Stage) were scheduled to be enrolled after fully informed and signed informed consent Qualified subjects were selected to receive the standard XELOX or SOX regimen selected by the investigators according to the disease and postoperative pathology of the subjects for 4 cycles, followed by the sequential treatment of monotherapy tislelizumab (200mg,Q3W, IV infusion,4 cycles) starting from 4-6 weeks after surgery, with a maximum of 12 weeks Safety assessments such as ECOG physical examination of vital signs and laboratory tests will be performed regularly during treatment
Study NCT05408312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine 1
Description: Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
Study NCT05539651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD5044
Description: Subcutaneously Administered RBD5044 in Healthy Subjects
Study NCT05539651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously Administered Placebo in Healthy Subjects
Study NCT06297876 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling
Description: Narrative stories will be videos that are 2-3 minutes long and will show community members speaking based on community identified themes.
Study NCT06297876 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Learn More (Active Comparator)
Description: Informational videos that are of similar length and on the same topic as the storytelling videos.
Study NCT04662164 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hepalatide
Description: 3 different dosage will be given sequentially to T2D patients
Study NCT04662164 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hepalatide
Description: 3 different dosage will be given sequentially to T2D patients
Study NCT05222685 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better Together Physician Coaching
Description: Professional group coaching for medical trainees. A 6 month, online, group, positive psychology based coaching program for wellness.
Study NCT04887675 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: Both groups with undergo neuroimaging on 3T magnetic resonance unit (Trio Tim, Siemens, Erlangen, Germany) in the Center for Diagnostic Imaging, Oncology Institute of Vojvodina, Serbia. Multivoxel MRS will be performed in the supratentorial cerebral parenchyma, covering white matter of frontal and parietal lobes, as well as cortical grey matter in frontal and parietal lobes and the whole cingulate gyrus.
Study NCT04692909 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dTMS with mPFC stimulation
Description: dTMS with Brainsway's H7 device, stimulating the mPFC.
Study NCT04692909 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: dTMS with mPFC stimulation
Description: dTMS with Brainsway's H7 device, stimulating the mPFC.
Study NCT05408312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine 2
Description: Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
Study NCT05408312 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Experimental Vaccine 3
Description: Intramuscular injection of low-dose Recombinant SARS-CoV-2 Vaccine (CHO cells，NVSI-06-08) in the deltoid muscle of the upper arm
Study NCT05408312 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular injection of low-dose Recombinant placebo in the deltoid muscle of the upper arm
Study NCT05759780 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical imaging of the tissues
Description: OCT vibrography
Study NCT06564584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-2716 Dose 1
Description: Capsules administered orally
Study NCT06564584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLC-2716 Dose 2
Description: Capsules administered orally
Study NCT06564584 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules administered orally
Study NCT05233839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Application based video home exercise for the degenerative meniscus injury
Study NCT05233839 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Paper Based Rehabilitation
Description: Paper instruction based home exercise for the degenerative meniscus injury
Study NCT06009302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided block of mandibular nerve
Description: Extraoral ultrasound-guided block of the mandibular nerve will be performed in the examined group using an ultrasound device, using ropivacaine (0.75%, 2.5 mL).
Study NCT06009302 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoral block of lower alveolar nerve
Description: Block of lower alveolar nerve will be applied intraoraly using articaine+adrenaline
Study NCT05170971 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: fecal microbiota transplantation
Description: The fecal bacteria were transplanted once every 5 days for a total of 4 times
Study NCT04858581 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Virological and serological tests
Description: Survey, RT-PCR test and blood test
Study NCT04655157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: encorafenib
Description: A small molecule BRAF inhibitor that targets key enzymes in the MAPK signaling pathway.
Study NCT04655157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: A programmed death receptor-1 (PD-1) blocking monoclonal antibody that works by helping the immune system to slow or stop the growth of cancer cells.
Study NCT04655157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: A monoclonal antibody medication that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system.
Study NCT04655157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: binimetinib
Description: A small molecule, selective inhibitor of MEK, a central kinase in the tumor-promoting MAPK pathway that may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Study NCT04158089 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babies and Moms connected through Love, Openness, and Opportunity (BLOOM)
Description: Participants will be randomly assigned into one of two groups for the BLOOM intervention; the control group will receive treatment as usual. Participants assigned to the treatment group will receive texted attachment exercises to complete from home. The intervention will take place over a 2-week period. Participants in the Attachment Exercises group will receive a text every day with an activity designed to increase feelings of attachment (e.g., read a children's book; sign a nursery rhyme; picture giving your baby a baby; tell your baby a story, etc.).
Study NCT05059886 — intervention group
Intervention type: OTHER
Intervention: completion of a questionnaire on the practice of sports and possible injuries
Description: completion of a questionnaire on the practice of sports and possible injuries
Study NCT05270525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensifentrine
Description: Ensifentrine twice daily administered with jet nebulizer for 8 weeks
Study NCT05270525 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo ensifentrine twice daily administered with jet nebulizer for 8 weeks
Study NCT05874726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Collection
Description: Blood collection via venipuncture
Study NCT05874726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Collection
Description: Free catch urine sample collection
Study NCT05874726 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Tissue Sample Collection
Description: Tissue (gastric, duodenum, jejunum and ileum - number of biopsies will be 3-4 from each site, ranging in size from 4-7mm) - These samples collected will be extra biopsies that are taken for research purposes during a clinically planned endoscopy for which biopsies are being planned.
Study NCT06484504 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kombucha beverage
Description: After 4-weeks of consuming a beige diet (i.e. low-fiber, low polyphenol diet), 20 subjects (kombucha group) will consume one bottle (two servings) of kombucha daily for 4 weeks and 10 subjects (control group) will not change their dietary habits
Study NCT05905172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone capsules
Description: After randomization, the experimental group received hydronidone capsules three times a day, 3 capsules each time, for 5 years.
Study NCT05905172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: The placebo capsules
Description: After randomization, The control group received three placebo capsules three times a day. 3 capsules each time, for 5 years.
Study NCT05407571 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Significance of Echogenic Amniotic Fluid on Perinatal Outcome
Description: To estimate the nature of echogenic amniotic fluid.and To overcome unnecessary intervention due to turbid amniotic fluid, assess neonatal outcome and estimate gestational age at time of delivery in patients with echogenic amniotic fluid.
Study NCT06190522 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Emergency physician clinical ultrasound
Description: Clinical ultrasound by emergency doctor consisting in obtaining frontal sections of the 2 kidneys and a transverse section of the bladder
Study NCT05801133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: 200 mg TID in the first week, 300 mg TID in the second week, and maintenance treatment of 400 mg TID from the third week until 3 months
Study NCT06303908 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple Gymnastics Training
Description: This is a simple gymnastics training that includes body swings and waist twists, as well as exercises targeting the joints in the arms and legs in various directions. It aims to help Parkinson's patients improve their physical mobility. Each training session lasts for 30 minutes, with low intensity and easy to stick to.
Study NCT05350410 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HALT-AD
Description: HALT-AD is an online educational program designed to teach about dementia and lifestyle changes that can help preserve brain health and lower dementia risk. Participants complete online courses and engage in facilitated discussion groups.
Study NCT06472206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHW Sessions
Description: Sessions with a Community Health Worker (CHW).
Study NCT05914545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FZ-AD004
Description: Dose Escalation：Subjects will receive an intravenous infusion of FZ-AD004 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study.~Dose Expansion：Subject will receive a single dose of FZ-AD004 at 1-2 dose level on Day1 of each cycles.
Study NCT05862272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relugolix Combination Tablet
Description: A fixed-dose combination tablet containing relugolix 40 mg, estradiol (E2) 1 mg, and norethindrone acetate (NETA) 0.5 mg.
Study NCT05962450 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNKT Cells
Description: the iNKT cells will be intravenous infused every two weeks as a course of treatment for up to six courses , the reinfusion dose is determined according to the patient's body surface area, which was about 108\~109cells/m2.
Study NCT05962450 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PD-1
Description: Intravenous infusion, according to the drug instructions.
Study NCT06472206 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CleverCap
Description: The CleverCap pill bottle is an innovative technology that dispenses only the prescribed amount of medication, keeps track of medications dispensed, and communicates wirelessly with the WiseApp to deliver medication adherence reminders.
Study NCT04930718 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thumb active Exercises
Description: Active específico exercises; Reeducation program
Study NCT04930718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thumb active Exercises
Description: Active específico exercises; Reeducation program
Study NCT04479969 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Video Chat
Description: Video chat with health coach using a computer tablet.
Study NCT06478238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium folinate
Description: Intravenous infusion and/or oral therapy
Study NCT00851708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: 600 mg bid orally from day 1 to 7 postoperative
Study NCT05962450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: Intravenous infusion, according to the drug instructions.
Study NCT05475041 — intervention group
Intervention type: PROCEDURE
Intervention: Major liver resection
Description: Major liver resection (3 or more contiguous segments)
Study NCT05475041 — intervention group
Intervention type: PROCEDURE
Intervention: Technically major liver resection
Description: Minor liver resection (\<3 contiguous segments) in the posterosuperior segments (segment 1,4a,7,8)
Study NCT04996043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Collagen Peptide Drink
Description: Testing product
Study NCT04996043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drink
Description: Blank
Study NCT05962450 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib
Description: Oral administration, according to the drug instructions.
Study NCT05962450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Oral administration, according to the drug instructions.
Study NCT06026852 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Prediction of plasma concentration of piperacillin-tazobactam or meropenem
Description: For included patients, a prediction will be made by developed machine learning models about the expected plasma concentration of piperacillin-tazobactam or meropenem by using routinely collected health care data.
Study NCT06026852 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Determination of plasma concentration of piperacillin-tazobactam or meropenem
Description: For included patients, the total plasma concentration of piperacillin-tazobactam or meropenem will be determined. Were possible, this will be done using a blood sample that was collected during routine daily bloodwork which is performed in the morning. If no routine sample is available, a study specific sample will be drawn at approximately the same time as a routine sample would be drawn.
Study NCT06026852 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Daily short questionnaire
Description: Physicians who care for patients included in the study will be asked to fill in a short daily questionnaire that evaluates the perceived necessity and added value of daily therapeutic drug monitoring.
Study NCT04528199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]FLOR (FC303) Injection
Description: Single dose of 10 ±1 millicurie (mCi) of \[18F\]FLOR (FC303) injection followed by the PET/CT scan.
Study NCT05513963 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clairity
Description: Treatment group participants will complete study session using the Clairity tool in between regularly scheduled therapy visits.